157 related articles for article (PubMed ID: 14663006)
1. Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease.
Standaert DG
Neurology; 2003 Dec; 61(11 Suppl 6):S30-1. PubMed ID: 14663006
[No Abstract] [Full Text] [Related]
2. Can adenosine A
Kanda T; Jenner P
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
[TBL] [Abstract][Full Text] [Related]
3. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.
Ongini E
Neurology; 2003 Dec; 61(11 Suppl 6):S72-3. PubMed ID: 14663015
[No Abstract] [Full Text] [Related]
5. Role of adenosine A
Pinna A; Serra M; Morelli M; Simola N
J Neural Transm (Vienna); 2018 Aug; 125(8):1273-1286. PubMed ID: 29396609
[TBL] [Abstract][Full Text] [Related]
6. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Bezard E; Brotchie JM; Gross CE
Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
[TBL] [Abstract][Full Text] [Related]
8. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
Schwartz M; Sabetay S
Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological interactions between adenosine A
Pinna A; Serra M; Marongiu J; Morelli M
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S37-S44. PubMed ID: 33349579
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A2A antagonists in Parkinson's disease: what's next?
Hickey P; Stacy M
Curr Neurol Neurosci Rep; 2012 Aug; 12(4):376-85. PubMed ID: 22585137
[TBL] [Abstract][Full Text] [Related]
11. How do adenosine A
Mori A
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S13-S20. PubMed ID: 33349575
[TBL] [Abstract][Full Text] [Related]
12. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
14. Should levodopa be used anymore?
Zegers de Beyl D
Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
[TBL] [Abstract][Full Text] [Related]
15. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
[TBL] [Abstract][Full Text] [Related]
16. Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.
Oki M; Kaneko S; Morise S; Takenouchi N; Hashizume T; Tsuge A; Nakamura M; Wate R; Kusaka H
Neurosci Res; 2017 Sep; 122():45-50. PubMed ID: 28577977
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of the basal ganglia in Parkinson's disease.
Obeso JA; Rodríguez-Oroz MC; Rodríguez M; Lanciego JL; Artieda J; Gonzalo N; Olanow CW
Trends Neurosci; 2000 Oct; 23(10 Suppl):S8-19. PubMed ID: 11052215
[TBL] [Abstract][Full Text] [Related]
18. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
[TBL] [Abstract][Full Text] [Related]
19. When and how should treatment be started in Parkinson disease?
Lang AE
Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
[TBL] [Abstract][Full Text] [Related]
20. [The use of piribedil in early and late stages of Parkinson's disease].
Fedorova NV; Kulua TK; Gubanova ЕN
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):96-98. PubMed ID: 26525631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
